Goar Gevorkian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Goar Gevorkian has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Gonzalo Acero
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), CDMX, MEXICO
7 shared publicationsMiryam Nava Catorce
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Apartado Postal 70228, Cuidad Universitaria, CDMX, CP 04510, Mexico
5 shared publicationsAdrian Rodriguez-Lopez
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), CDMX, MEXICO
3 shared publications- José Luna-Muñoz
BioBanco Nacional de Demencias, Universidad Politécnica de Pachuca, Zempoala, México
3 shared publications Karen Manoutcharian
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), CDMX, MEXICO
3 shared publicationsRoxanna Perez-Garmendia
Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Mexico DF. Mexico
3 shared publications
Latest Publications
- Open Access
- 4 September 2025
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 27 (1) , 1-10
Splenomegaly, Spleen Amyloidosis and Neutrophil Infiltration are Present in 3xTg-AD, but not Tg-SwDI Mice
It is now widely accepted that the development of neurodegenerative diseases depends on and affects many pathological processes, both in the brain and the periphery. Inflammatory, cardiovascular, metabolic, cerebrovascular, autoimmune, and other environmental factors have been extensively studied and shown to contribute notably to the onset, pathogenesis, and clinical outcome of Alzheimer´s disease (AD), Parkinson´s disease (PD), cerebral amyloid angiopathy (CAA), multiple sclerosis, and other neurological disorders. Likewise, AD-induced changes in other tissues outside the central nervous system, such as abnormalities observed in the liver, spleen, or lungs, have been documented and extensively studied, leading to a better understanding of brain-periphery crosstalk in neurodegenerative diseases and the development of novel diagnostic and therapeutic approaches. In this study, we documented striking differences in the periphery in two frequently used, well-established APP transgenic mouse models of AD: 3xTg-AD mice, harboring three human genes (APP, tau, and Psen1), and Tg-SwDI mice, expressing human APP with the Swedish and vasculotropic Dutch/Iowa mutations in the brain. We documented splenomegaly, immunoglobulin-associated spleen amyloidosis, and an increase in the percentage of neutrophils in the spleen and macrophages in the liver in 3xTg-AD mice but not in age-matched Tg-SwDI mice, which are commonly used as an AD/CAA model. Our data suggest that the results observed in any transgenic mouse strain should be taken into account with caution. A detailed knowledge of pathological characteristics recapitulated in a particular strain can help to determine which mice are more appropriate for studying a specific mechanism or therapeutic approach.
- 4 September 2025
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 27 (1) , 1-10
Open AccessSplenomegaly, Spleen Amyloidosis and Neutrophil Infiltration are Present in 3xTg-AD, but not Tg-SwDI Mice
It is now widely accepted that the development of neurodegenerative diseases depends on and affects many pathological processes, both in the brain and the periphery. Inflammatory, cardiovascular, metabolic, cerebrovascular, autoimmune, and other environmental factors have been extensively studied and shown to contribute notably to the onset, pathogenesis, and clinical outcome of Alzheimer´s disease (AD), Parkinson´s disease (PD), cerebral amyloid angiopathy (CAA), multiple sclerosis, and other neurological disorders. Likewise, AD-induced changes in other tissues outside the central nervous system, such as abnormalities observed in the liver, spleen, or lungs, have been documented and extensively studied, leading to a better understanding of brain-periphery crosstalk in neurodegenerative diseases and the development of novel diagnostic and therapeutic approaches. In this study, we documented striking differences in the periphery in two frequently used, well-established APP transgenic mouse models of AD: 3xTg-AD mice, harboring three human genes (APP, tau, and Psen1), and Tg-SwDI mice, expressing human APP with the Swedish and vasculotropic Dutch/Iowa mutations in the brain. We documented splenomegaly, immunoglobulin-associated spleen amyloidosis, and an increase in the percentage of neutrophils in the spleen and macrophages in the liver in 3xTg-AD mice but not in age-matched Tg-SwDI mice, which are commonly used as an AD/CAA model. Our data suggest that the results observed in any transgenic mouse strain should be taken into account with caution. A detailed knowledge of pathological characteristics recapitulated in a particular strain can help to determine which mice are more appropriate for studying a specific mechanism or therapeutic approach.
- 18 February 2025
- Published by Elsevier in Experimental Neurology
- Vol. 387, 115189
Tg-SwDI transgenic mice: A suitable model for Alzheimer's disease and cerebral amyloid angiopathy basic research and preclinical studies
- 18 February 2025
- Published by Elsevier in Experimental Neurology
- Vol. 387, 115189
Tg-SwDI transgenic mice: A suitable model for Alzheimer's disease and cerebral amyloid angiopathy basic research and preclinical studies
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 22 (13) , 2157-2167
Recombinant Antibody Fragments for Neurological Disorders: An Update
: Recombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating big opportunities for the pharmaceutical industry. Nowadays, antibody fragments such as antigen-binding fragments (Fab), single-chain fragment variable (scFv), single-domain antibodies (sdAbs), and bispecific antibodies (bsAbs) are being evaluated as diagnostics or therapeutics in preclinical models and in clinical trials. Immunotherapy approaches, including passive transfer of protective antibodies, have shown therapeutic efficacy in several animal models of Alzheimer´s disease (AD), Parkinson´s disease (PD), frontotemporal dementia (FTD), Huntington´s disease (HD), transmissible spongiform encephalopathies (TSEs) and multiple sclerosis (MS). There are various antibodies approved by the Food and Drug Administration (FDA) for treating multiple sclerosis and two amyloid beta-specific humanized antibodies, Aducanumab and Lecanemab, for AD. Our previous review summarized data on recombinant antibodies evaluated in pre-clinical models for immunotherapy of neurodegenerative diseases. Here, we explore recent studies in this fascinating research field, give an update on new preventive and therapeutic applications of recombinant antibody fragments for neurological disorders and discuss the potential of antibody fragments for developing novel approaches for crossing the blood-brain barrier (BBB) and targeting cells and molecules of interest in the brain.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 22 (13) , 2157-2167
Recombinant Antibody Fragments for Neurological Disorders: An Update
: Recombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating big opportunities for the pharmaceutical industry. Nowadays, antibody fragments such as antigen-binding fragments (Fab), single-chain fragment variable (scFv), single-domain antibodies (sdAbs), and bispecific antibodies (bsAbs) are being evaluated as diagnostics or therapeutics in preclinical models and in clinical trials. Immunotherapy approaches, including passive transfer of protective antibodies, have shown therapeutic efficacy in several animal models of Alzheimer´s disease (AD), Parkinson´s disease (PD), frontotemporal dementia (FTD), Huntington´s disease (HD), transmissible spongiform encephalopathies (TSEs) and multiple sclerosis (MS). There are various antibodies approved by the Food and Drug Administration (FDA) for treating multiple sclerosis and two amyloid beta-specific humanized antibodies, Aducanumab and Lecanemab, for AD. Our previous review summarized data on recombinant antibodies evaluated in pre-clinical models for immunotherapy of neurodegenerative diseases. Here, we explore recent studies in this fascinating research field, give an update on new preventive and therapeutic applications of recombinant antibody fragments for neurological disorders and discuss the potential of antibody fragments for developing novel approaches for crossing the blood-brain barrier (BBB) and targeting cells and molecules of interest in the brain.
- 13 February 2024
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 96, 101254
Are we getting closer to a successful neoantigen cancer vaccine?
- 13 February 2024
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 96, 101254
Are we getting closer to a successful neoantigen cancer vaccine?
- Open Access
- 27 January 2024
- Published by Springer Nature in BioDrugs
- Vol. 38 (2) , 249-257
Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease
Parkinson’s disease (PD) is the second most common age-related neurodegenerative disorder. Multiple genetic and environmental factors leading to progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SN) and consequent depletion of dopamine were described. Current clinical approaches, such as dopamine replacement or deep brain stimulation using surgically implanted probes, provide symptomatic relief but cannot modify disease progression. Therefore, disease-modifying therapeutic tools are urgently needed. Immunotherapy approaches, including passive transfer of protective antibodies and their fragments, have shown therapeutic efficacy in several animal models of neurodegenerative diseases, including PD. Recombinant antibody fragments are promising alternatives to conventional full-length antibodies. Modern computational approaches and molecular biology tools, directed evolution methodology, and the design of tissue-penetrating fusion peptides allowed for the development of recombinant antibody fragments with superior specificity and affinity, reduced immunogenicity, the capacity to target hidden epitopes and cross the blood-brain barrier (BBB), higher solubility and stability, the ability to refold after heat denaturation, and inexpensive large-scale production. In addition, antibody fragments do not induce microglia Fcγ receptor (FcγR)-mediated proinflammatory response and tissue damage in the central nervous system (CNS), because they lack the Fc portion of the immunoglobulin molecule. In the present review, we summarized data on recombinant antibody fragments evaluated as immunotherapeutics in preclinical models of PD and discussed their potential for developing therapeutic and preventive protocols for patients with PD.
- 27 January 2024
- Published by Springer Nature in BioDrugs
- Vol. 38 (2) , 249-257
Open AccessRecombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease
Parkinson’s disease (PD) is the second most common age-related neurodegenerative disorder. Multiple genetic and environmental factors leading to progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SN) and consequent depletion of dopamine were described. Current clinical approaches, such as dopamine replacement or deep brain stimulation using surgically implanted probes, provide symptomatic relief but cannot modify disease progression. Therefore, disease-modifying therapeutic tools are urgently needed. Immunotherapy approaches, including passive transfer of protective antibodies and their fragments, have shown therapeutic efficacy in several animal models of neurodegenerative diseases, including PD. Recombinant antibody fragments are promising alternatives to conventional full-length antibodies. Modern computational approaches and molecular biology tools, directed evolution methodology, and the design of tissue-penetrating fusion peptides allowed for the development of recombinant antibody fragments with superior specificity and affinity, reduced immunogenicity, the capacity to target hidden epitopes and cross the blood-brain barrier (BBB), higher solubility and stability, the ability to refold after heat denaturation, and inexpensive large-scale production. In addition, antibody fragments do not induce microglia Fcγ receptor (FcγR)-mediated proinflammatory response and tissue damage in the central nervous system (CNS), because they lack the Fc portion of the immunoglobulin molecule. In the present review, we summarized data on recombinant antibody fragments evaluated as immunotherapeutics in preclinical models of PD and discussed their potential for developing therapeutic and preventive protocols for patients with PD.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
The AβpE 3‐42 peptide is associated with a higher degree of inflammation than Aβ1‐40 in brains with Alzheimer’s disease.
Background: Alzheimer’s Disease (AD) is the most common neurodegenerative disease histopathologically characterized by the presence of neuritic plaques (NPs), extracellular deposits composed of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFTs) composed of tau protein. It has been hypothesized that Aβ promotes synthesis and secretes proinflammatory proteins causing neuronal and endothelial damage in the AD brain. In this context, it is not clear if the truncated Aβ species can be more toxic than the full‐length ones. Therefore, this work aimed to explore the association of the Aβ1‐40 peptide (full length) and AβpE3‐42 (truncated species) with inflammation in the brains of AD patients.Method: We used postmortem tissue from the temporal cortex of patients with AD and it was analyzed by confocal microscopy using antibodies against the peptide Aβ 1‐40 and AβpE 3‐42, phospho tau and caspase‐5 (inflammatory type caspase). The amyloidogenic plaques AB1‐40 and AβpE3‐42 and their association with the inflammation marker caspase 5 were quantified. In addition, caspase 5 was quantified by western blot (WB) in control brains and those with AD.Result: We found high caspase‐5 immunoreactivity specifically associated with extracellular Aβ peptide deposits. Interestingly, this caspase 5 is associated preferentially with the truncated Aβ pE 3‐42 peptide. Likewise, caspase‐5 was expressed mainly in brain blood vessels which had Aβ peptide deposits. We did not detect the colocalization of this enzyme with the tau protein. WB assays show increased caspase 5 in AD brains compared to controls.Conclusion: In conclusion, our findings show that the truncated AβpE3‐42 peptide is closely associated with caspase 5, a key enzyme in the inflammation process. This latter may be a specific biomarker of inflammation in AD brains.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessThe AβpE 3‐42 peptide is associated with a higher degree of inflammation than Aβ1‐40 in brains with Alzheimer’s disease.
Background: Alzheimer’s Disease (AD) is the most common neurodegenerative disease histopathologically characterized by the presence of neuritic plaques (NPs), extracellular deposits composed of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFTs) composed of tau protein. It has been hypothesized that Aβ promotes synthesis and secretes proinflammatory proteins causing neuronal and endothelial damage in the AD brain. In this context, it is not clear if the truncated Aβ species can be more toxic than the full‐length ones. Therefore, this work aimed to explore the association of the Aβ1‐40 peptide (full length) and AβpE3‐42 (truncated species) with inflammation in the brains of AD patients.Method: We used postmortem tissue from the temporal cortex of patients with AD and it was analyzed by confocal microscopy using antibodies against the peptide Aβ 1‐40 and AβpE 3‐42, phospho tau and caspase‐5 (inflammatory type caspase). The amyloidogenic plaques AB1‐40 and AβpE3‐42 and their association with the inflammation marker caspase 5 were quantified. In addition, caspase 5 was quantified by western blot (WB) in control brains and those with AD.Result: We found high caspase‐5 immunoreactivity specifically associated with extracellular Aβ peptide deposits. Interestingly, this caspase 5 is associated preferentially with the truncated Aβ pE 3‐42 peptide. Likewise, caspase‐5 was expressed mainly in brain blood vessels which had Aβ peptide deposits. We did not detect the colocalization of this enzyme with the tau protein. WB assays show increased caspase 5 in AD brains compared to controls.Conclusion: In conclusion, our findings show that the truncated AβpE3‐42 peptide is closely associated with caspase 5, a key enzyme in the inflammation process. This latter may be a specific biomarker of inflammation in AD brains.
- 9 May 2023
- Published by Elsevier in Fish & Shellfish Immunology
- Vol. 138, 108808
Shark VNAR phage display libraries: An alternative source for therapeutic and diagnostic recombinant antibody fragments
- 9 May 2023
- Published by Elsevier in Fish & Shellfish Immunology
- Vol. 138, 108808
Shark VNAR phage display libraries: An alternative source for therapeutic and diagnostic recombinant antibody fragments
- Open Access
- 1 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3654
Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease Brains
Alzheimer’s disease (AD) is a neurodegenerative disease, characterized histopathologically by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in the brain parenchyma and around cerebral blood vessels. According to the vascular hypothesis of AD, an alteration in the neurovascular unit (NVU) could lead to Aβ vascular accumulation and promote neuronal dysfunction, accelerating neurodegeneration and dementia. To date, the effects of insoluble vascular Aβ deposits on the NVU and the blood–brain barrier (BBB) are unknown. In this study, we analyze different Aβ species and their association with the cells that make up the NVU. We evaluated post-mortem AD brain tissue. Multiple immunofluorescence assays were performed against different species of Aβ and the main elements that constitute the NVU. Our results showed that there are insoluble vascular deposits of both full-length and truncated Aβ species. Besides, insoluble aggregates are associated with a decrease in the phenotype of the cellular components that constitute the NVU and with BBB disruption. This approach could help identify new therapeutic targets against key molecules and receptors in the NVU that can prevent the accumulation of vascular fibrillar Aβ in AD.
- 1 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3654
Open AccessInsoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease Brains
Alzheimer’s disease (AD) is a neurodegenerative disease, characterized histopathologically by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in the brain parenchyma and around cerebral blood vessels. According to the vascular hypothesis of AD, an alteration in the neurovascular unit (NVU) could lead to Aβ vascular accumulation and promote neuronal dysfunction, accelerating neurodegeneration and dementia. To date, the effects of insoluble vascular Aβ deposits on the NVU and the blood–brain barrier (BBB) are unknown. In this study, we analyze different Aβ species and their association with the cells that make up the NVU. We evaluated post-mortem AD brain tissue. Multiple immunofluorescence assays were performed against different species of Aβ and the main elements that constitute the NVU. Our results showed that there are insoluble vascular deposits of both full-length and truncated Aβ species. Besides, insoluble aggregates are associated with a decrease in the phenotype of the cellular components that constitute the NVU and with BBB disruption. This approach could help identify new therapeutic targets against key molecules and receptors in the NVU that can prevent the accumulation of vascular fibrillar Aβ in AD.